Canagliflozin: Efficacy and Safety in Combination with Metformin Alone or with Other Antihyperglycemic Agents in Type 2 Diabetes

por Qiu, Rong, Balis, Dainius, Capuano, George, Xie, John, Meininger, Gary
Publicado 2016

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome

por Davies, Michael J, Merton, Katherine W, Vijapurkar, Ujjwala, Balis, Dainius A, Desai, Mehul
Publicado 2017

Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus

por Desai, Mehul, Yavin, Yshai, Balis, Dainius, Sun, Don, Xie, John, Canovatchel, William, Rosenthal, Norm
Publicado 2017

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

por Weir, Matthew R, Slee, April, Sun, Tao, Balis, Dainius, Oh, Richard, de Zeeuw, Dick, Perkovic, Vlado
Publicado 2020